Phenprocoumon Dose Requirements, Dose Stability and Time in Therapeutic Range in Elderly Patients With CYP2C9 and VKORC1 Polymorphisms-Reference-Cited by-同舟云学术

Phenprocoumon Dose Requirements, Dose Stability and Time in Therapeutic Range in Elderly Patients With CYP2C9 and VKORC1 Polymorphisms

Published:2020-01-28 Issue: Volume:10 Page:
ISSN:1663-9812
Container-title:Frontiers in Pharmacology
language:
Short-container-title:Front. Pharmacol.

Author:

Schneider Katharina Luise,Kunst Melanie,Leuchs Ann-Kristin,Böhme Miriam,Weckbecker Klaus,Kastenmüller Kathrin,Bleckwenn Markus,Holdenrieder Stefan,Coch Christoph,Hartmann Gunther,Stingl Julia Carolin

Funder

Bundesministerium für Bildung und Forschung

Publisher

Frontiers Media SA

Subject

Pharmacology (medical),Pharmacology

Reference29 articles.

1. Quantifying the effect of covariates on concentrations and effects of steady-state phenprocoumon using a population pharmacokinetic/pharmacodynamic model;Abduljalil;Clin. Pharmacokinet.,2013

2. Pharmacology and management of the vitamin K antagonists: american college of chest physicians evidence-based clinical practice guidelines (8th edition);Ansell;Chest,2008

3. Dosing algorithms for vitamin K antagonists across VKORC1 and CYP2C9 genotypes;Baranova;J. Thromb. Haemostasis: JTH,2017

4. Genetic variations of phenprocoumon metabolism in patients with ventricular assist devices;Brehm;Eur. J. Cardiothorac. Surg.,2016

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Pharmacokinetics of Phenprocoumon in Emergency Situations–Results of the Prospective Observational RADOA-Registry (Reversal Agent Use in Patients Treated with Direct Oral Anticoagulants or Vitamin K Antagonists Registry);Pharmaceuticals;2022-11-19

2. Individualized versus Standardized Risk Assessment in Patients at High Risk for Adverse Drug Reactions (The IDrug Randomized Controlled Trial)–Never Change a Running System?;Pharmaceuticals;2021-10-18

3. Adverse Drug Reactions in the Emergency Department: Is There a Role for Pharmacogenomic Profiles at Risk?—Results from the ADRED Study;Journal of Clinical Medicine;2020-06-09